

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/578,384	LAWSON ET AL.	

  

<b>Examiner</b>	<b>Art Unit</b>	
Phillip Gambel	1644	

**All Participants:**

**Status of Application:** \_\_\_\_\_

(1) Phillip Gambel.

(3) \_\_\_\_\_.

(2) Sandra Weiss.

(4) \_\_\_\_\_.

**Date of Interview:** 11/26/2008

**Time:** \_\_\_\_\_

**Type of Interview:**

Telephonic

Video Conference

Personal (Copy given to:  Applicant     Applicant's representative)

Exhibit Shown or Demonstrated:  Yes     No

If Yes, provide a brief description: .

**Part I.**

Rejection(s) discussed:

n/a

Claims discussed:

n/a

Prior art documents discussed:

n/a

**Part II.**

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

**Part III.**

- It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
- It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

/Phillip Gambel/  
Primary Examiner, Art Unit 1644

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: examiner invited to elect a species of anti-CSF-1 with OR withOUT an additional anti-IBD therapeutic agent / anti-cancer agent and (elect a specific agent(s), if appropriate) as it reads on the elected method. applicant's representative elects methods of treating IBD with anti-CSF-1 antibody and withOUT an additional anti-IBD therapeutic agent / anti-cancer agent..